Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
05 February 2021Website:
http://www.immunocore.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
IMCR Latest News
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V.
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - Jefferies Elias Lenard - JPMorgan Tyler Van - TD Cowen Eric Schmidt - Cantor Fitzgerald Michael Schmidt - Guggenheim Jack Allen - Baird Justin Zelin - BTIG Jonathan Chang - Leerink Securities Ahu Demir - Ladenburg Thalmann Avantika Joshi - Mizuho Naureen Quibria - Capital One Securities Rajan Sharma - Goldman Sachs Ethan Markowski - Needham & Company Operator Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What type of business is Immunocore Holdings?
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
What sector is Immunocore Holdings in?
Immunocore Holdings is in the Healthcare sector
What industry is Immunocore Holdings in?
Immunocore Holdings is in the Biotechnology industry
What country is Immunocore Holdings from?
Immunocore Holdings is headquartered in United Kingdom
When did Immunocore Holdings go public?
Immunocore Holdings initial public offering (IPO) was on 05 February 2021
What is Immunocore Holdings website?
https://www.immunocore.com
Is Immunocore Holdings in the S&P 500?
No, Immunocore Holdings is not included in the S&P 500 index
Is Immunocore Holdings in the NASDAQ 100?
No, Immunocore Holdings is not included in the NASDAQ 100 index
Is Immunocore Holdings in the Dow Jones?
No, Immunocore Holdings is not included in the Dow Jones index
When was Immunocore Holdings the previous earnings report?
No data
When does Immunocore Holdings earnings report?
The next expected earnings date for Immunocore Holdings is 28 February 2025